Enzymicals AG announces management transition of the CEO to the Supervisory Board

29. May 2024

BRAIN Biotech AG and Enzymicals AG are pleased to announce that Dr. Erik de Vries will join BRAIN Biotech as Senior Business Development Director Enzymes as of June 1st, 2024. De Vries will continue in his current position as CEO of Enzymicals AG on a part-time basis during a transition phase until the end of the year.


A succession plan is being implemented. A new CEO will take over the duties from Erik de Vries from January 1st, 2025. Following the handover of the CEO position at Enzymicals, it is planned to have Erik de Vries appointed to the Supervisory Board of Enzymicals AG as a representative of BRAIN Biotech AG at the 2025 Annual General Meeting.


Prof. Dr. Uwe Bornscheuer, Chairman of the Supervisory Board of Enzymicals AG, states: “Erik de Vries has done an excellent job since he started in early 2022 as a CEO of Enzymicals as reflected in the record revenues and numerous new projects being under way. At the Supervisory Board, we are very grateful for his valuable input thanks to his decades long experience in biocatalysis and business development. I am confident that Enzymicals will continue along this path in the future and very much look forward to having Erik de Vries on the Board from 2025.”


More information: 20240529_PI_BRAIN_Erik de Vries as SBD Director Enzymes_EN